Is ATOS or ATRA more undervalued in 2026?

CirclFi compares Atossa Therapeutics, Inc. (ATOS) and Atara Biotherapeutics, Inc. (ATRA) using 13 institutional-grade valuation models. ATOS has a Quality of Company score of 4.5/10 while ATRA scores 4.8/10.

Which is a better buy — ATOS or ATRA?

Compare intrinsic values from 13 independent models against current market prices. CirclFi also calculates Value Trap scores. This is not financial advice — conduct your own analysis.

How do ATOS and ATRA valuations compare?

ATOS at $5.19 and ATRA at $11.26 are compared across Bayesian DCF, EPV, EROIC Spread, First Chicago, Markov DDM, and 8 additional models.

ATOS vs ATRA Valuation Comparison 2026 — Intrinsic Value Analysis

ATOS

Biotechnology

Atossa Therapeutics, Inc.

Quality

4.5

out of 10

Value Trap

SAFE

Price

$5.19

Last close

Models

7/13

Active

ATRA

Biotechnology

Atara Biotherapeutics, Inc.

Quality

4.8

out of 10

Value Trap

SAFE

Price

$11.26

Last close

Models

11/13

Active

Model-by-Model Comparison

Model	Type	ATOS Fair Value	ATOS Upside	ATRA Fair Value	ATRA Upside
Bayesian DCF	Intrinsic	$3.40	-34.4%	$2.31	-79.5%
Earnings Power Value	Intrinsic	—	—	$49.72	+496.1%
EROIC Spread	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
First Chicago	Scenario	$•••.••	••.•%	$•••.••	••.•%
ML-RIV	Intrinsic	$0.52	-90.2%	—	—
Dynamic NAV	Asset-Based	$•••.••	••.•%	$•••.••	••.•%
PWERM	Option-Based	$•••.••	••.•%	$•••.••	••.•%
Regime Cross-Sectional	Relative	$•••.••	••.•%	$•••.••	••.•%
Sentiment SOTP	Hybrid	$•••.••	••.•%	$•••.••	••.•%
CUCE Ensemble	Ensemble	$•••.••	••.•%	$•••.••	••.•%
FTNN Topology	Relative	$•••.••	••.•%	$•••.••	••.•%
RCMH-DCF	Intrinsic	$•••.••	••.•%	$•••.••	••.•%

🔒

Unlock Full 13-Model Comparison

Access all valuation models for ATOS vs ATRA — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

ATOS vs ATRA — Which Stock Is More Undervalued?

ATRA scores higher with a 4.8/10 quality rating vs ATOS's 4.5/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Atossa Therapeutics, Inc. (ATOS) and Atara Biotherapeutics, Inc. (ATRA) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

ATOS currently trades at $5.19 with a QOC of 4.5/10, while ATRA trades at $11.26 with a QOC of 4.8/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).